Probiotic Strain Lactobacillus casei BL23 Prevents Colitis-Associated Colorectal Cancer.
Probiotic Strain Lactobacillus casei BL23 Prevents Colitis-Associated Colorectal Cancer.
复制标题
DOI：
10.3389/fimmu.2017.01553
复制
发表时间：
2017
影响因子：
7.3
通讯作者：
Bermúdez-Humarán LG
中科院分区：
文献类型：
--
作者：
Jacouton E;Chain F;Sokol H;Langella P;Bermúdez-Humarán LG
肠道微生物群在肠道健康中起着重要作用，其组成的不平衡可能导致慢性肠道炎症和患结直肠癌（CRC）的倾向。目前，益生菌的使用代表了治疗和预防癌症的新兴替代方案。此外，这些有益细菌的消耗也可以有利地调节肠道微生物群的组成，这在几项研究中被描述为在CRC致癌作用中发挥重要作用。在这种情况下，本研究的目的是评估口服干酪乳杆菌BL 23的保护作用，干酪乳杆菌BL 23是一种以其抗炎和抗癌特性而闻名的益生菌菌株。首先，通过单次腹腔注射氧化偶氮甲烷（8 mg/kg），随后通过饮用水中的葡聚糖硫酸钠（2.5%）的四个疗程在C57 BL 6小鼠中诱导CRC，所述四个疗程由可调节的恢复期隔开。在处死时（第46天），在结肠样品中测定肿瘤发生率、组织学评分和上皮增殖。结果表明，L. casei BL 23显著保护小鼠免受CRC发展;具体地，L.干酪素BL 23处理降低了组织学评分和增殖指数值。此外，我们的分析表明L.酪蛋白BL 23具有通过下调IL-22细胞因子介导的免疫调节作用和通过上调半胱天冬酶-7、半胱天冬酶-9和Bik介导的抗增殖作用。最后，L。干酪素BL 23处理倾向于平衡小鼠中CRC诱导的生态失调，如粪便微生物群分析所证明的。总之，我们的结果表明，L。casei BL 23用于开发新的基于益生菌的策略来对抗CRC。
The gut microbiota plays a major role in intestinal health, and an imbalance in its composition can lead to chronic gut inflammation and a predisposition to developing colorectal cancer (CRC). Currently, the use of probiotic bacteria represents an emerging alternative to treat and prevent cancer. Moreover, consumption of these beneficial bacteria may also favorably modulate the composition of the gut microbiota, which has been described in several studies to play an important role in CRC carcinogenesis. In this context, the aim of this study was to assess the protective effect of oral treatment with Lactobacillus casei BL23, a probiotic strain well known for its anti-inflammatory and anticancer properties. First, CRC was induced in C57BL6 mice by a single intraperitoneal injection with azoxymethane (8 mg/kg), followed by four courses of dextran sodium sulfate (2.5%) in drinking water that were separated by an adjustable recovery period. At the time of sacrifice (day 46), tumor incidence, histological scores, and epithelial proliferation were determined in colon samples. Our results show that L. casei BL23 significantly protected mice against CRC development; specifically, L. casei BL23 treatment reduced histological scores and proliferative index values. In addition, our analysis revealed that L. casei BL23 had an immunomodulatory effect, mediated through the downregulation of the IL-22 cytokine, and an antiproliferative effect, mediated through the upregulation of caspase-7, caspase-9, and Bik. Finally, L. casei BL23 treatment tended to counterbalance CRC-induced dysbiosis in mice, as demonstrated by an analysis of fecal microbiota. Altogether our results demonstrate the high potential of L. casei BL23 for the development of new, probiotic-based strategies to fight CRC.